Updated:
215 Capital
215 Capital is a full life-cycle investment firm with three verticals: Operations Portfolio, Incubation Platform, and Investment Fund. The firm empowers...
215 Capital
215 Capital is a full life-cycle investment firm with three verticals: Operations Portfolio, Incubation Platform, and Investment Fund. The firm empowers companies that find cures for deadly diseases in pharmaceuticals, healthcare and life sciences. Its team deploys clinical, commercial and operational domain expertise, capital, and resources to promising companies addressing unmet medical need.
General information
Firm type
Private Equity
Year founded
2016
Location
Region
North America
Country
United States
City
Philadelphia
Corporate office
Philadelphia, PA, United States
Principals
Ajay Raju
Founder
David Cochran
Ph.D., Director, Pharma and Biotech Investments
Ricky Yang
Chief Financial Officer
Rob Davis
Compliance
Ranjeesh Gopinathan
Board, Portfolios
Rudy Karsan
Partner
Ted Hailu
Chief Administrative Officer
Amit Shah
Director, Pharma and Life Sciences Investments
Jeffrey Lee
Chief Accounting Officer
Aaron Mahdee
Operations
Junge Zhang
Ph.D., Board
Melissa Anagnostakos
Chief Operating Officer
William Hunter
General Counsel
Manru Wang
Chief of Staff
Satya Ganti
Ph.D., Board, Portfolios
Rajiv Savara
Board
Sector focus
Frequently asked questions
What investment stages does 215 Capital target?
215 Capital invests from seed stage through late-stage growth. The approach is generalist across venture and expansion capital, with no publicly stated minimum or maximum check size. Their flexibility allows them to support companies from initial product development through scaling phases.
Which sectors does 215 Capital focus on?
The firm concentrates on enterprise software, fintech, and digital health, with additional activity observed in AI/ML. They have not indicated a strict sector exclusion policy. No investments in hardware, industrials, or consumer goods have been identified.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: